Breda, The Netherlands / Ghent, Belgium, April 14, 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces the resignation of Non-executive Directors Dr. Bruno Montanari and Dr. Harrold van Barlingen from the Board of Directors per 13 May 2015.

 

Dr. Van Barlingen has been involved with arGEN-X B.V. since 2008, Dr. Montanari joined as a supervisory director of arGEN-X B.V. in 2012. In line with the requirements of the Dutch Corporate Governance Code, both directors will be replaced by independent industry professionals.

 

As announced on 1 April, Dr. J. Donald deBethizy shall be recommended for appointment as Non-executive Director to the Board during the Annual Meeting of Shareholders on 13 May 2015.

Furthermore, arGEN-X announces that Dr. Pamela Klein has agreed to serve as an advisor to the Board of Directors as from 13 May 2015. Dr. Klein is an experienced biotech and pharma executive with successful stints at Genentech as Vice President Oncology and at Intellikine as Chief Medical Officer. 

 

The Board of arGEN-X intends to recommend Dr. Klein for appointment as Non-executive Director to the Board at the next shareholders' meeting following the Annual Meeting of 13 May 2015.

“I have great confidence that the new Board will be instrumental in taking arGEN-X to the next level and continuing to build significant value for our shareholders. I would also like to take this opportunity to thank Bruno and Harrold for their very important contributions as Directors over the past years,” commented Peter Verhaeghe, Chairman of the Board of Directors.

 

About arGEN-X

arGEN-X is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. arGEN-X has generated a pipeline of differentiated clinical and preclinical antibody candidates using its SIMPLE Antibody™ discovery platform. SIMPLE Antibody™ has a particular strength in addressing novel, complex disease targets that are difficult to access using established antibody technology platforms. Proprietary Fc engineering technologies (NHance® and ABDEG™) and POTELLIGENT® technology (licensed from BioWa, Inc.) further enhance the therapeutic properties of SIMPLE Antibody™ leads in terms of tissue penetration/residence time in the body, ability to clear disease targets or pathogenic antibodies and cell-killing potency through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), respectively. arGEN-X has leveraged its suite of antibody technologies in forging strategic collaborations with pharmaceutical and biotechnology companies to provide new approaches to diseases with unmet medical needs.

 

arGEN-X is listed on the Euronext Brussels exchange under the symbol ARGX.
www.arGEN-X.com

 

SIMPLE Antibody™, NHance® and ABDEG™ are trademarks of arGEN-X NV

POTELLIGENT® is a trademark of BioWa Inc. 

 

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements arGEN-X makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. arGEN-X’ actual results may differ materially from those predicted by the forward-looking statements. arGEN-X undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.